American chemical industry news

• 

  20 March 2026

  Siemens invests $165M to expand U.S. AI infrastructure manufacturing

  Expands manufacturing in NC and SC, adds 350+ jobs, scales prefabricated power distribution, medium‑voltage protection and busway systems for data centers; starts Careers Electric training.
• 

  20 March 2026

  FUCHS posts solid FY 2025 results

  FY2025: sales €3.56bn, EBIT €435m; EPS +2%; dividend +5% to €1.23/€1.22; free cash flow €316m. 2026 outlook: sales ~€3.7bn, EBIT ~€450m
• 

  19 March 2026

  FDA approves Novo Nordisk’s Wegovy HD (7.2 mg) after ~21% weight loss in STEP UP trial

  Higher‑dose semaglutide injection approved for adults with obesity after tolerating 2.4 mg; 31% reached ≥25% weight loss. Common AEs: GI symptoms and dysesthesia/altered skin sensation. Available April.
• 

  19 March 2026

  Genmab: Board constituted; grants RSUs and warrants to employees

  Deirdre P. Connelly named Chair; Pernille Erenbjerg Deputy Chair. 5,213 RSUs (DKK1,645/share) and 4,485 warrants (exercise DKK1,645; Black‑Scholes value DKK530.62). Vesting in 3 years.
• 

  19 March 2026

  Novo Nordisk: FDA approves Wegovy HD (semaglutide 7.2 mg) — 20.7% mean weight loss

  STEP UP: ~31% achieved ≥25% loss; STEP UP T2D mean loss 14.1%. FDA awarded National Priority Voucher. US launch expected April 2026. Safety/tolerability comparable to prior semaglutide doses.
• 

  19 March 2026

  GSK: Lynavoy (linerixibat) FDA-approved for cholestatic pruritus in PBC

  FDA approved linerixibat for cholestatic pruritus in adults with PBC after GLISTEN phase III showed rapid, sustained itch and sleep improvements. Common AEs: diarrhea, abdominal pain.

• 

  19 March 2026

  Iberdrola hits 11 GW U.S. generation capacity

  Nearly 100 U.S. facilities across 25 states, capacity meets >7M Americans; added 850 MW recently. Plans €16B investment (2025-28) for grids and new generation.
• 

  19 March 2026

  Clariant opens pharma-grade PEG manufacturing plant in Texas

  GMP-compliant excipient production strengthens supply-chain resilience, shortens lead times, and improves continuity and traceability for pharma customers across North & Latin America.
• 

  19 March 2026

  Equinor Annual Report 2025

  Record production and strong cash results in 2025; safety improved; adjusted operating income $27.6B; production 2,137 mboe/d; renewables +25%; emissions −34% since 2015.
• 

  19 March 2026

  Sumitomo Corporation to Deploy Palantir AIP for OCTG Supply Chain DX

  AI/data platform to optimize OCTG supply chain—inventory, processing and billing. Europe pilot validated; rollout from FY2026 with phased function and regional expansion.
• 

  18 March 2026

  TotalEnergies Annual Shareholders' Meeting — May 29, 2026

  Board convenes May 29 meeting; renews three directors for 3 years; appoints Slawomir Krupa to replace Mark Cutifani; seeks to raise chair/CEO age limits; submits pay, finance and sustainability items.
• 

  18 March 2026

  Eni 2025 Financial Statements

  Board approved 2025 Annual Report: consolidated net profit €2,608m, parent €4,429m. 4th dividend scheduled (ex-div May 18, pay May 20). AGM May 6; governance, sustainability and remuneration reports to be published.
• 

  18 March 2026

  BASF divests Aseptrol biocide business to Oxidium Technologies

  Aseptrol chlorine dioxide portfolio sold; terms undisclosed. New owner will expand the technology into additional industries. Formulations, labeling, approvals and supply remain unchanged.
• 

  18 March 2026

  Johnson & Johnson FDA approves ICOTYDE (icotrokinra) for first‑line systemic treatment of plaque psoriasis

  First targeted oral IL‑23 receptor peptide approved for moderate‑to‑severe plaque psoriasis in adults and ≥12 (≥40kg). Once‑daily pill; ~70% IGA0/1, 55% PASI90 at Week16; safety like placebo.
• 

  18 March 2026

  Technip Energies acquires minority stake in Verso Energy’s DEZiR eSAF plant in Rouen

  Project will use carbon capture to source biogenic CO2 and has FEED underway; plant due ~2030 to produce 80,000 t/yr eSAF, backed by France 2030/EU fund and planned for replication.
• 

  17 March 2026

  PPG’s Laura Harshberger named to 2026 Pittsburgh Business Times Women of Influence

  Global IT director Laura Harshberger honored on 2026 list; led IT for operations, EHS and key businesses, modernized systems at 100+ sites, runs IT internship program and champions women's leadership.
• 

  17 March 2026

  Eni secures €9bn 5-year revolving credit facility

  €9bn 5‑year revolver with 2‑year extension option refinancing prior €6bn and €3bn lines; provided by 28 banks, ~40% oversubscription, maintains financial flexibility and extends maturity
• 

  17 March 2026

  Worley to Engineer Donlin Gold Gas Pipeline

  Worley Alaska will design a 316-mile natural gas pipeline for the Donlin Gold project, ensuring energy supply in remote, challenging terrain. Completion of feasibility study is set for 2027.
• 

  16 March 2026

  Terumo Aortic's Fenestrated TREO® Gains FDA Breakthrough Status

  The FDA's Breakthrough Device Designation accelerates the review of Fenestrated TREO®, a custom stent-graft for complex abdominal aortic aneurysms, offering a tailored, minimally invasive solution.
• 

  16 March 2026

  Roche Unveils NVIDIA-Powered AI Factory for Therapeutics and Diagnostics

  Roche expands its AI infrastructure with 2,176 NVIDIA GPUs, enhancing drug development, diagnostics, and manufacturing through advanced computing and AI integration.
• 

  16 March 2026

  bp Starts Gas Production at Angola's Quiluma Field

  Initial production is 150 mmscf/day, ramping to 330 mmscf/day by 2026. The project is Angola's first non-associated gas development, enhancing its global natural gas market position.
• 

  16 March 2026

  Lilly's EBGLYSS Achieves Positive Phase 3 Results in Pediatric Atopic Dermatitis

  EBGLYSS shows significant skin improvement and itch relief in children with moderate-to-severe atopic dermatitis, meeting primary and secondary endpoints in Phase 3 ADorable-1 trial.
• 

  16 March 2026

  LANXESS Showcases Cosmetics and Personal Care Portfolio at in-cosmetics Global

  LANXESS highlights preservation solutions, sustainable ingredients, and global production capabilities for cosmetics and personal care at the Paris trade fair.
• 

  16 March 2026

  Arkema Boosts Kynar® PVDF Capacity in China

  Arkema expands Changshu site by 20% to meet rising demand in Asia-Pacific for Kynar® PVDF, targeting EV batteries, coatings, and more, with a 2028 start-up.
• 

  14 March 2026

  Ørsted's Revolution Wind Powers New England Grid

  Revolution Wind delivers 704 MW to New England, powering 350,000 homes, stabilizing prices, and supporting 2,000 jobs. Expected to save $500M annually in energy costs.
• 

  13 March 2026

  Trinseo 2025 Q4 and Full-Year Financial Results

  Q4 net loss of $251M, full-year loss of $546M. Sales down 19% in Q4, 15% annually. Restructuring costs impacted results. Adjusted EBITDA stable in Q4, down $41M annually.
• 

  13 March 2026

  GSK's Arexvy RSV Vaccine Approved for Expanded Use in US Adults 18-49

  FDA expands Arexvy's use to adults 18-49 at risk for severe RSV. Phase III trials show efficacy and safety. 17,000 hospitalizations annually in this age group.
• 

  12 March 2026

  Fluor Opens Bucharest Office to Boost Nuclear Energy Projects in Europe

  Fluor's new Bucharest office will enhance its capacity to deliver nuclear energy projects, supporting Romania's clean energy goals and leveraging local strategic advantages.
• 

  12 March 2026

  Johnson & Johnson's TECNIS PureSee IOL Gains FDA Approval for Cataract Surgery

  TECNIS PureSee IOL offers enhanced vision for cataract patients, reducing reliance on glasses and maintaining contrast sensitivity, with 97% reporting no bothersome visual disturbances.
• 

  12 March 2026

  Evonik and IMCD Expand U.S. Distribution for VISIOMER® Methacrylates

  IMCD will distribute VISIOMER® Specialty Methacrylates in the U.S., enhancing support for coatings, adhesives, construction, and more.